Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) reached a new 52-week high on Thursday . The stock traded as high as $98.44 and last traded at $97.86, with a volume of 1439128 shares trading hands. The stock had previously closed at $88.07.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. Wedbush set a $165.00 price objective on Oruka Therapeutics in a report on Monday, April 27th. BTIG Research reissued a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Monday, July 13th. Weiss Ratings upgraded Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, April 30th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $134.30.
Get Our Latest Stock Analysis on ORKA
Oruka Therapeutics Trading Up 11.1%
Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. Analysts expect that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.
Insider Buying and Selling
In related news, SVP Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock in a transaction dated Monday, July 13th. The stock was sold at an average price of $84.63, for a total transaction of $846,215.37. Following the completion of the sale, the senior vice president owned 15,312 shares in the company, valued at approximately $1,295,854.56. This trade represents a 39.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $69.69, for a total transaction of $120,494.01. Following the completion of the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at $64,503,670.20. The trade was a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 188,406 shares of company stock valued at $12,019,683 over the last three months. Insiders own 23.49% of the company’s stock.
Institutional Investors Weigh In On Oruka Therapeutics
Several hedge funds have recently modified their holdings of the company. Legal & General Group Plc purchased a new stake in shares of Oruka Therapeutics during the second quarter worth about $28,000. BNP Paribas Financial Markets lifted its stake in shares of Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after buying an additional 2,306 shares during the period. Royal Bank of Canada boosted its position in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in Oruka Therapeutics during the fourth quarter worth approximately $37,000. Finally, PNC Financial Services Group Inc. purchased a new stake in Oruka Therapeutics in the 3rd quarter worth approximately $39,000. 56.44% of the stock is owned by institutional investors and hedge funds.
Oruka Therapeutics Company Profile
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
